This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.
Antengene is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class and best-in-class therapies for hematologic malignancies and solid tumors with significant unmet medical needs.
Antengene Corporation Limited (SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class and best-in-class therapeutics for diseases with significant unmet medical needs. Our pipeline spans from preclinical to commercial stages and includes several in-house discovered programs.
Developing innovative cancer medicines to treat patients beyond borders worldwide.
Building fully-integrated capabilities in discovery, clinical development, manufacturing, and commercialization to foster the rapid clinical adoption of innovative medicines for the benefit of broad patient populations.
Our proprietary platforms and in-house discovery programs are driving the next generation of targeted cancer therapies.
A proprietary T cell engager 2.0 platform featuring:
Supports broad applicability across autoimmune diseases, solid tumors, and hematological malignancies.
Phase II program efficacious in Claudin 18.2 ultra-low expressors
Oral small molecule with robust PoC data in reversing anti-PD-1 resistance
Bispecific antibody overcoming liver toxicity
First-in-class macrophage activator targeting CD24-expressing solid tumors
From discovery to commercialization, our pipeline is designed to deliver transformative therapies to patients worldwide.
Approved in 10 markets including Mainland China, Hong Kong, South Korea, Singapore, and Australia. Used in multiple myeloma and DLBCL.
Claudin 18.2-targeting antibody-drug conjugate (ADC) for gastric/GEJ cancers, including ultra-low expressors.
Oral CD73 inhibitor with potential to reverse resistance to anti-PD-1 therapies in melanoma and NSCLC.
Bispecific antibody targeting PD-L1 and 4-1BB, designed to overcome liver toxicity seen in other 4-1BB agonists.
First-in-class macrophage activator targeting CD24-expressing solid tumors, harnessing innate immunity.
Oral PRMT5-MTA inhibitor with potential in hematologic and solid tumors.
Multiple T cell engager candidates in development for autoimmune and oncology indications.
Multiple trials across Asia and the U.S. in gastric cancer, lymphoma, melanoma, and NSCLC.
Stay informed about Antengene’s latest clinical milestones, regulatory approvals, and partnerships.
Expanding access in multiple myeloma and diffuse large B-cell lymphoma.
Read More →Phase Ib/II trial evaluating combination in gastric cancer patients.
Read More →Showcasing encouraging clinical data and progress across investigational programs.
Read More →Antengene is working closely with global partners to usher in the next wave of biopharmaceutical innovation.
If you are interested in partnering with Antengene, please contact us at [email protected].
Email Partnership TeamFor business development, media inquiries, or career opportunities, visit the official Antengene website to connect with the team.
Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.
For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact [email protected] via your corporate email to cancel. We will cancel your inclusion within 3 business days.
如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系[email protected] 取消收录 我们将在3个工作日取消您的收录
Service Request: If you are other domain and want to be included, please contact [email protected]
如果您是其他域名合作 也请联系[email protected]
